Differentiating Acinetobacter baumannii from Other Acinetobacter Species Matters

In the world of infectious diseases, diligence isn’t just a scientific ideal, it’s a clinical necessity. Among the many bacterial pathogens that challenge healthcare systems, Acinetobacter species stand out for their ability to cause severe infections and develop resistance to multiple antibiotics. But here’s the key: not all Acinetobacter species behave the same way. Understanding the difference between Acinetobacter baumannii (ABB) and non-baumannii Acinetobacter (NBAB) species can dramatically affect patient outcomes.

The clinical stakes

ABB is notorious for its multidrug-resistant (MDR) and extensively drug-resistant (XDR) profiles. Studies show that only about 4% of ABB isolates remain susceptible to carbapenems, often forcing clinicians to rely on last-line drugs associated with toxicity and limited efficacy.

By contrast, NBAB species such as A. nosocomialis or A. pittii, typically show much lower resistance rates, with 88–90% remaining susceptible to carbapenems. This means that standard antibiotics can often be used effectively, reducing the need for toxic alternatives.¹

Misidentification hurts

Mistaking NBAB for ABB can lead to unnecessarily aggressive therapy, exposing patients to harmful side effects and accelerating antimicrobial resistance. On the other hand, underestimating ABB’s resistance can result in inappropriate empirical therapy—a factor strongly linked to higher mortality.²

Rapid identification: A game-changer

Traditional biochemical methods can take days to differentiate species; time critically ill patients do not have. 

The LIAISON PLEX^® Gram-Negative Blood Culture Assay is the first multiplex molecular test that differentiates Acinetobacter baumannii from other NBAB species in a single run. Advanced multiplex molecular tests like this allow clinicians to identify species within hours, enabling prompt/timely targeted therapy. Evidence suggests that starting effective treatment early can reduce mortality threefold.² 

Beyond identification: Stewardship and survival

Differentiating ABB from NBAB is not about choosing the right drug; it’s about aligning with antimicrobial stewardship principles. Accurate identification prevents over-treatment, refines antibiotic use, and helps curb the spread of resistance.

Key Takeaways

• Resistance matters: ABB is highly resistant; NBAB is generally susceptible.
• Clinical impact: ABB infections often lead to severe outcomes and higher mortality.
• Therapy decisions: Rapid, species-specific identification improves survival and reduces unnecessary toxicity.

Precision saves lives. As diagnostic technologies advance, integrating rapid species identification and differentiation into routine workflows is no longer optional, it’s essential.

Learn more about the LIAISON PLEX^® Gram-Negative Blood Culture Assay.

You may also be interested in this blog: It’s Time to Incorporate Klebsiella variicola into Your Bloodstream Infection Testing.